MCP AbD Serotec
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on December 1, 2005.
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
M500213-MCP200v1
4/12/1942    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Glossary
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janzi, M.
Right arrow Articles by Nilsson, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janzi, M.
Right arrow Articles by Nilsson, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on July 14, 2005
Revised on August 18, 2005
Accepted on August 29, 2005

Serum microarrays for large scale screening of protein levels

Magdalena Janzi, Jenny Ödling, Qiang Pan-Hammarström, Mårten Sundberg, Joakim Lundeberg, Mathias Uhlen, Lennart Hammarström, and Peter Nilsson

Molecular Biotechnology, KTH - Royal Institute of Technology, Stockholm SE-10691

Corresponding Author: peter.nilsson{at}biotech.kth.se

There is a great need for comprehensive proteomics analysis of large patient cohorts of plasma and serum samples to identify biomarkers of human diseases. Here, we describe a new antibody-based proteomics approach involving a reverse array format, where serum samples are spotted on a microarray. This enables all samples to be screened for its content of a certain serum protein in a single experiment using target recognizing antibodies and fluorescently labelled secondary antibodies. The procedure is illustrated with the analysis of the IgA-levels in 2009 spotted serum samples and the data are compared with clinical routine measurements. The results suggest that it is possible to simultaneously screen thousands of complex clinical serum samples for their content of the relative amount of specific serum proteins of clinical relevance.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
W.-J. Qian, J. M. Jacobs, T. Liu, D. G. Camp II, and R. D. Smith
Advances and Challenges in Liquid Chromatography-Mass Spectrometry-based Proteomics Profiling for Clinical Applications
Mol. Cell. Proteomics, October 1, 2006; 5(10): 1727 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Sanchez-Carbayo
Antibody Arrays: Technical Considerations and Clinical Applications in Cancer
Clin. Chem., September 1, 2006; 52(9): 1651 - 1659.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.